Cargando…

S37. STATE-DEPENDENT EFFECTS OF D2 PARTIAL AGONIST ARIPIPRAZOLE ON DOPAMINE NEURON ACTIVITY IN THE MAM NEURODEVELOPMENTAL MODEL OF SCHIZOPHRENIA

BACKGROUND: Aripiprazole is an antipsychotic drug characterized by partial agonist activity at D2 receptors that impacts both hyperdopaminergic and hypodopaminergic states. It is unclear whether aripiprazole reduces dopamine neuron activity via inhibition or by excitation-induced depolarization bloc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sonnenschein, Susan, Gill, Kathryn, Grace, Anthony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888288/ http://dx.doi.org/10.1093/schbul/sby018.824

Ejemplares similares

Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia
por: Takase, Masayuki, et al.
Publicado: (2015)

Place of the partial dopamine receptor agonist aripiprazole in the management of schizophrenia in adults: a Delphi consensus study
por: Llorca, Pierre-Michel, et al.
Publicado: (2022)

S232. ALPHA7 NICOTINIC RECEPTOR AGONISTS REVERSE THE HYPERDOPAMINERGIC STATE IN THE MAM MODEL OF SCHIZOPHRENIA
por: Neves, Gilda, et al.
Publicado: (2018)

Discovery research and development history of the dopamine D(2) receptor partial agonists, aripiprazole and brexpiprazole
por: Kikuchi, Tetsuro, et al.
Publicado: (2021)

Case report: Open bite as an extrapyramidal side effect with aripiprazole, a dopamine partial agonist
por: Sumi, Satoko, et al.
Publicado: (2022)

Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)
por: Kelly, Deanna L, et al.
Publicado: (2013)

Early Blockade of CB1 Receptors Ameliorates Schizophrenia-like Alterations in the Neurodevelopmental MAM Model of Schizophrenia
por: Stark, Tibor, et al.
Publicado: (2022)

Dysregulation of Midbrain Dopamine System and the Pathophysiology of Schizophrenia
por: Sonnenschein, Susan F., et al.
Publicado: (2020)

Loss of Parvalbumin in the Hippocampus of MAM Schizophrenia Model Rats Is Attenuated by Peripubertal Diazepam
por: Du, Yijuan, et al.
Publicado: (2016)

Medial septum activation produces opposite effects on dopamine neuron activity in the ventral tegmental area and substantia nigra in MAM vs. normal rats
por: Bortz, David M., et al.
Publicado: (2018)

Nicotine Administration Normalizes Behavioral and Neurophysiological Perturbations in the MAM Rodent Model of Schizophrenia
por: Weeks, Jillian J, et al.
Publicado: (2021)

Effects of Dopamine D(2) Receptor Partial Agonist Antipsychotic Aripiprazole on Dopamine Synthesis in Human Brain Measured by PET with L-[β-(11)C]DOPA
por: Ito, Hiroshi, et al.
Publicado: (2012)

Adult stress exposure blunts dopamine system hyperresponsivity in a neurodevelopmental rodent model of schizophrenia
por: Rincón-Cortés, Millie, et al.
Publicado: (2022)

Active-State Model of a Dopamine D(2) Receptor - Gα(i) Complex Stabilized by Aripiprazole-Type Partial Agonists
por: Kling, Ralf C., et al.
Publicado: (2014)

Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse
por: Spiros, Athan, et al.
Publicado: (2010)

Use of prepubertal environment enrichment to prevent dopamine dysregulation in a neurodevelopmental rat model of schizophrenia risk
por: Zhu, Xiyu, et al.
Publicado: (2022)

S40. MEDIAL SEPTUM ACTIVATION PRODUCES OPPOSITE EFFECTS ON DOPAMINE NEURON ACTIVITY IN THE VENTRAL TEGMENTAL AREA AND SUBSTANTIA NIGRA PARS COMPACTA IN MAM VERSUS NORMAL RATS
por: Bortz, David, et al.
Publicado: (2018)

Aripiprazole for late-life schizophrenia
por: Rado, Jeffrey, et al.
Publicado: (2010)

Review of depot aripiprazole for schizophrenia
por: Motiwala, Farha Bilal, et al.
Publicado: (2013)

Agonist and Antagonist Effects of Aripiprazole on D(2)-Like Receptors Controlling Rat Brain Dopamine Synthesis Depend on the Dopaminergic Tone
por: Ma, Guo Fen, et al.
Publicado: (2015)

Sex-Specific Cannabidiol- and Iloperidone-Induced Neuronal Activity Changes in an In Vitro MAM Model System of Schizophrenia
por: Thériault, Rachel-Karson, et al.
Publicado: (2021)

The novel atypical antipsychotic cariprazine demonstrates dopamine D(2) receptor‐dependent partial agonist actions on rat mesencephalic dopamine neuronal activity
por: Delcourte, Sarah, et al.
Publicado: (2018)

Aripiprazol and Hypersexuality: when partial is to much
por: Espada-Santos, P., et al.
Publicado: (2022)

Long-term Effects of Aripiprazole Treatment during Adolescence on Cognitive Function and Dopamine D2 Receptor Expression in Neurodevelopmentally Normal Rats
por: Choi, Hyung Jun, et al.
Publicado: (2019)

Role of aripiprazole in treatment-resistant schizophrenia
por: Mossaheb, Nilufar, et al.
Publicado: (2012)

Pyk2 Regulates MAMs and Mitochondrial Dynamics in Hippocampal Neurons
por: López-Molina, Laura, et al.
Publicado: (2022)

T180. REDUCED [3H]RO15-4513 RECEPTOR BINDING IN THE VENTRAL HIPPOCAMPUS IN THE MAM DEVELOPMENTAL DISRUPTION MODEL OF SCHIZOPHRENIA
por: Kiemes, Amanda, et al.
Publicado: (2020)

Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?
por: Mohr, Pavel, et al.
Publicado: (2022)

Binding kinetics of cariprazine and aripiprazole at the dopamine D(3) receptor
por: Frank, Annika, et al.
Publicado: (2018)

The relationship between dopamine receptor blockade and cognitive performance in schizophrenia: a [(11)C]-raclopride PET study with aripiprazole
por: Shin, Sangho, et al.
Publicado: (2018)

Aripiprazole: the evidence of its therapeutic impact in schizophrenia
por: Winlow, William, et al.
Publicado: (2006)

Effect of Aripiprazole on Mismatch Negativity (MMN) in Schizophrenia
por: Zhou, Zhenhe, et al.
Publicado: (2013)

Aripiprazole-associated tic in a schizophrenia patient
por: Guo, Xieli, et al.
Publicado: (2015)

Successful treatment of dopamine dysregulation syndrome with dopamine D(2) partial agonist antipsychotic drug
por: Mizushima, Jin, et al.
Publicado: (2012)

Ta yol Mam : txolil ta tsi'b'enj te ta yol mam = Norma de escritura de la lengua mam.
Publicado: (2011)

Behavioral Mechanisms That Depend on Dopamine and Serotonin in Caenorhabditis elegans Interact With the Antipsychotics Risperidone and Aripiprazole
por: Osuna-Luque, Jaime, et al.
Publicado: (2018)

The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study
por: Hashimoto, Kojiro, et al.
Publicado: (2014)

Identifying dopamine supersensitivity through a randomized controlled study of switching to aripiprazole from other antipsychotic agents in patients with schizophrenia
por: Ma, Chia-Hao, et al.
Publicado: (2022)

Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
por: Hattori, Saki, et al.
Publicado: (2023)

Molecular Imaging of Dopamine Partial Agonists in Humans: Implications for Clinical Practice
por: Hart, Xenia M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4solaesc860llta8hq6l5kj89c